USP18 Inhibition Enhances Type I Interferon Signalling and Immune Activation in the Tumour Microenvironment of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant breast cancers. Although immunotherapy has emerged as a promising treatment option, clinical benefit is limited, with only around half of patients responding, even when combined with standard chemotherapeutic agents. This limited efficacy is often attributed to immunologically "cold" tumour microenvironments (TME), which are resistant to current immunotherapies. Addressing this challenge requires approaches that can reprogram "cold" TMEs into "hot" immune-responsive states. USP18, a negative regulator of type I interferon (IFN) signalling, suppresses immune activation by removing ISG15 from target proteins and disrupting IFNAR-STAT2 interactions. Here, we show that both genetic ablation and catalytic inactivation of USP18 enhance type I IFN signalling in TNBC cells, leading to sustained STAT1/STAT2 phosphorylation. This increased IFN responsiveness promotes antigen presentation via MHC-I upregulation and increases expression of pro-apoptotic ligands such as FAS. Proteomic profiling and immunophenotyping revealed that USP18 inhibition in vivo reduces tumour growth and increases immunogenicity, accompanied by cancer-immune infiltration modulation including CD8 T cells, Th1 cells, NK cells, cDC1, and pro-inflammatory M1-like macrophages. These changes reflect a shift in the TME from an immunosuppressive to an immunostimulatory state, driven by heightened and prolonged type I IFN signalling. Our findings highlight the therapeutic potential of USP18 inhibition to convert immunologically "cold" tumours into "hot" tumours, by enhancing IFN-driven immune activation and improving the efficacy of immunotherapy in TNBCs.